AIM ImmunoTech Inc AIM
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
AIM ImmunoTech Highlights Ampligen® Opportunity to Potentially Extend Benefits of RAS-Targeted Therapies in Pancreatic Cancer
AIM ImmunoTech’s Strategy to Address Immune Resistance in Pancreatic Cancer Featured in BioTuesdays
AIM ImmunoTech Highlights Recent Media Coverage of Ampligen’s® Broad-Spectrum Antiviral and Biodefense Potential
AIM ImmunoTech Spotlights Growing Attention Around Ampligen® Pancreatic Cancer Strategy as DURIPANC Advances Toward Topline Data
AIM ImmunoTech Discusses Ampligen®’s Potential to Complement Emerging Pancreatic Cancer Therapies in New CEO Corner Video
AIM ImmunoTech Highlights Ampligen’s Potential Role in the Evolving Pancreatic Cancer Treatment Landscape Following FDA Approval of Revolution Medicines’ Daraxonrasib
AIM ImmunoTech Highlights Scientific Rationale, Supportive Data and Continued Advancement of Ampligen® in Pancreatic Cancer in New CEO Corner Video
AIM ImmunoTech Significantly Expands Ampligen® Global Patent Estate with Long COVID Protection Across Europe and the United Kingdom Through 2041
Trading Information
- Previous Close Price
- $0.16
- Day Range
- $0.15–0.17
- 52-Week Range
- $0.15–2.02
- Bid/Ask
- $0.15 / $0.16
- Shares Outstanding
- 39.89M
- Market Cap
- $6.07M
- Volume/Avg
- 1M / 5M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 10.67
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
AIM ImmunoTech Inc is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders, and to treat cancers for which there are currently inadequate or unmet therapies. Its flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) molecule being developed for globally important cancers, viral diseases, and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 21
- Website
- https://www.aimimmuno.com
Valuation
Metric | AIM |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.57 |
Price/Sales | 10.67 |
Price/Cash Flow | — |
Price/Earnings
AIM
Financial Strength
Metric | AIM |
|---|---|
Quick Ratio | 2.01 |
Current Ratio | 2.11 |
Interest Coverage | −13.92 |
Quick Ratio
AIM
Profitability
Metric | AIM |
|---|---|
Return on Assets (Normalized) | −123.72% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −926.05% |
Return on Assets
AIM
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|q>g<nw | LOCK|Q?sv | $139B | |||
| Moderna Inc MRNA | LOCK|cVB%>>Z | LOCK|t^ | $103B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|G#dZ@?^ | LOCK|Pp&@q | $96B | |||
| argenx SE ADR ARGX | LOCK|z%zXQ^H | LOCK|^Nk | $57B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|QnkD^&> | LOCK|?lR | $45B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|MfQv$<nd | LOCK|^<?tx | $30B | |||
| Incyte Corp INCY | LOCK|LF&&XTM | LOCK|SY< | $25B | |||
| BioNTech SE ADR BNTX | LOCK|<^Bl<p | LOCK|?M | $22B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|M&bJ#$ | LOCK|SXpL | $22B | |||
| BridgeBio Pharma Inc BBIO | LOCK|HQc<lL | LOCK|>R | $15B |
United States